Tandem Diabetes Care (TNDM) Scheduled to Post Earnings on Thursday

Tandem Diabetes Care (NASDAQ:TNDM) is set to issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.80) per share for the quarter. Tandem Diabetes Care has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. The business had revenue of $196.80 million during the quarter, compared to analysts’ expectations of $204.86 million. On average, analysts expect Tandem Diabetes Care to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tandem Diabetes Care Trading Up 5.1 %

Shares of Tandem Diabetes Care stock opened at $37.05 on Tuesday. The company’s fifty day moving average is $31.21 and its two-hundred day moving average is $25.61. Tandem Diabetes Care has a 1 year low of $13.82 and a 1 year high of $40.74. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83. The company has a market capitalization of $2.39 billion, a P/E ratio of -10.77 and a beta of 1.11.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Wells Fargo & Company upgraded Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $21.00 to $45.00 in a research report on Monday. SVB Leerink upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $34.00 to $45.00 in a research note on Thursday, April 25th. Citigroup increased their target price on Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Leerink Partnrs upgraded Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 25th. Finally, StockNews.com raised Tandem Diabetes Care from a “sell” rating to a “hold” rating in a report on Friday, April 19th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.82.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.